journal
MENU ▼
Read by QxMD icon Read
search

Clinical Genitourinary Cancer

journal
https://www.readbyqxmd.com/read/29331381/clinical-outcomes-of-first-line-abiraterone-acetate-or-enzalutamide-for-metastatic-castration-resistant-prostate-cancer-after-androgen-deprivation-therapy%C3%A2-docetaxel-or-adt-alone-for-metastatic-hormone-sensitive-prostate-cancer
#1
Edoardo Francini, Steven Yip, Shubidito Ahmed, Haocheng Li, Luke Ardolino, Carolyn P Evan, Marina Kaymakcalan, Grace K Shaw, Philip W Kantoff, Mary-Ellen Taplin, Nimira S Alimohamed, Anthony M Joshua, Daniel Y C Heng, Christopher J Sweeney
BACKGROUND: The CHAARTED (ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) and STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent therapies is still unexplored. As abiraterone acetate (AA) and enzalutamide (E) are the most commonly used first-line treatment for metastatic castration-resistant prostate cancer (mCRPC), we aimed to assess whether they maintained their efficacy after ADT+D versus ADT alone...
December 27, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29329663/reintroducing-pazopanib-reverses-the-primary-resistance-of-nivolumab-in-a-patient-with-metastatic-clear-cell-renal-cell-carcinoma
#2
Harvey Yu-Li Su
No abstract text is available yet for this article.
December 21, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29325739/anti-programmed-cell-death-1-ligand-1-pd-1-pd-l1-antibodies-for-the-treatment-of-urothelial-carcinoma-state-of-the-art-and-future-development
#3
REVIEW
Thomas Powles, Andrea Necchi, Galit Rosen, Subramanian Hariharan, Andrea B Apolo
Immunotherapy with programmed cell death 1/ligand 1 (PD-1/PD-L1) checkpoint inhibitors has expanded a previously limited pool of effective treatment options for patients with metastatic urothelial carcinoma, particularly those with recurring or refractory disease and those who are ineligible for cisplatin. This review reports key findings from completed and ongoing clinical trials that highlight the potential of PD-1/PD-L1 blockade in urothelial carcinoma. A literature search was performed of PubMed, Embase, ClinicalTrials...
December 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29325738/the-effect-of-patient-and-surgical-characteristics-on-renal-function-after-partial-nephrectomy
#4
Andrew G Winer, Emily C Zabor, Michael J Vacchio, A Ari Hakimi, Paul Russo, Jonathan A Coleman, Edgar A Jaimes
BACKGROUND: The purpose of the study was to identify patient and disease characteristics that have an adverse effect on renal function after partial nephrectomy. PATIENTS AND METHODS: We conducted a retrospective review of 387 patients who underwent partial nephrectomy for renal tumors between 2006 and 2014. A line plot with a locally weighted scatterplot smoothing was generated to visually assess renal function over time. Univariable and multivariable longitudinal regression analyses incorporated a random intercept and slope to evaluate the association between patient and disease characteristics with renal function after surgery...
December 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29289519/contemporary-patterns-of-multidisciplinary-care-in-patients-with-muscle-invasive-bladder-cancer
#5
Lauren C Harshman, Abhishek Tripathi, Matthew Kaag, Jason A Efstathiou, Andrea B Apolo, Jean H Hoffman-Censits, Walter M Stadler, Evan Y Yu, Bernard H Bochner, Eila C Skinner, Tracy Downs, Anne E Kiltie, Dean F Bajorin, Khurshid Guru, William U Shipley, Gary D Steinberg, Noah M Hahn, Srikala S Sridhar
BACKGROUND: Multidisciplinary clinics integrate the expertise of several specialties to provide effective treatment to patients. This exposure is especially relevant in the management of muscle-invasive bladder cancer (MIBC), which requires critical input from urology, radiation oncology, and medical oncology, among other supportive specialties. MATERIALS AND METHODS: In the present study, we sought to catalog the different styles of multidisciplinary care models used in the management of MIBC and to identify barriers to their implementation...
December 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29289518/the-association-between-sarcopenia-and-oncologic-outcomes-after-radical-prostatectomy
#6
Ross J Mason, Stephen A Boorjian, Bimal Bhindi, Laureano Rangel, Igor Frank, R Jeffrey Karnes, Matthew K Tollefson
PURPOSE: Sarcopenia is associated with inferior perioperative and oncologic outcomes in patients undergoing surgery for multiple malignancies. The purpose of this study was to evaluate the association between sarcopenia and outcomes after radical prostatectomy (RP) for men with prostate cancer. PATIENTS AND METHODS: Using a representative computed tomographic image from the L3 level, preoperative skeletal muscle indices (SMI) calculated for 698 patients who underwent RP between 2007 and 2010...
December 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29287969/association-between-symptomatic-versus-asymptomatic-recurrence-and-survival-in-bladder-cancer
#7
Chelsea K Osterman, Jaber Alanzi, James D Lewis, Elizabeth L Kaufman, Vivek Narayan, Ben Boursi, Ravy K Vajravelu, Frank I Scott, S Bruce Malkowicz, Ronac Mamtani
BACKGROUND: The benefit of surveillance after curative cystectomy in bladder cancer is unproven, but might be justified if detection of asymptomatic recurrence improves survival. Previous studies showing a benefit of surveillance might have been affected by lead-time or length-time bias. MATERIALS AND METHODS: We conducted a retrospective cohort study among 463 cystectomy patients at the University of Pennsylvania. Patients were followed according to a standardized protocol and classified according to asymptomatic or symptomatic recurrence detection...
December 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29287968/dna-repair-pathway-alterations-in-metastatic-castration-resistant-prostate-cancer-responders-to-radium-223
#8
Jorge D Ramos, Elahe A Mostaghel, Colin C Pritchard, Evan Y Yu
No abstract text is available yet for this article.
December 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29276131/-18f-psma-1007-pet-improves-the-diagnosis-of-local-recurrence-and-lymph-node-metastases-in-a-prostate-cancer-patient-with-a-history-of-bilateral-hip-arthroplasty
#9
Frederik L Giesel, Leon Will, Kiryl Paddubny, Christophe Kremer, Hendrik Rathke, Jan P Radtke, Klaus Kopka, Sabine Haufe, Uwe Haberkorn, Clemens Kratochwil
No abstract text is available yet for this article.
December 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29274813/comparison-of-alternative-androgen-receptor-axis-targeted-agent-arata-and-docetaxel-as-second-line-therapy-for-patients-with-metastatic-castration-resistant-prostate-cancer-with-progression-after-initial-arata-in-real-world-clinical-practice-in-japan
#10
Hideaki Miyake, Takayuki Sugiyama, Ryota Aki, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Toshiki Ito, Atsushi Otsuka
BACKGROUND: The objective of the present study was to assess the oncologic outcomes of patients receiving second-line therapy against metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: The present study included 222 consecutive mCRPC patients with progression during initial androgen receptor-axis-targeted agent (ARATA) therapy with either abiraterone acetate (AA) or enzalutamide (Enz). Of these 222 patients, 108 subsequently received an alternative ARATA (AA-to-Enz, n = 49; Enz-to-AA, n = 59) and 114 received docetaxel (DTX; AA-to-DTX, n = 54; Enz-to-DTX, n = 60)...
December 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29198640/serum-testosterone-levels-in-prostate-cancer-patients-undergoing-luteinizing-hormone-releasing-hormone-agonist-therapy
#11
Juan Morote, Inma Comas, Jacques Planas, Xavier Maldonado, Ana Celma, José Placer, Roser Ferrer, Joan Carles, Lucas Regis
BACKGROUND: Serum testosterone measurement is recommended to assess the efficacy of androgen deprivation therapy (ADT) and to diagnose castration resistance in patients with prostate cancer (PCa). Currently, the accepted castrate level of serum testosterone is 50 ng/dL. Liquid chromatography and tandem mass spectrometry (LC MSMS) is the appropriate method to measure testosterone, especially at low levels. However, worldwide, chemiluminescent assays (CLIAs) are used in clinical laboratories, despite their lack of accuracy and reproducibility, because they are automatable, fast, sensitive, and inexpensive...
November 30, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29198639/baseline-multiparametric-mri-for-selection-of-prostate-cancer-patients-suitable-for-active-surveillance-which-features-matter
#12
Francesco Sanguedolce, Giuseppe Petralia, Heminder Sokhi, Elena Tagliabue, Nicola Anyamene, Giles Hellawell, Anwar R Padhani
INTRODUCTION: Increasing evidence has supported the use of multiparametric magnetic resonance imaging (mpMRI) for the detection of prostate cancer. However, its role in selecting patients clinically suitable for active surveillance (AS) is still in development. We aimed to find relevant mpMRI features that might be helpful for refinement of the selection of low-risk prostate cancer patients for AS. We also evaluated the interobserver variability in reporting prostate mpMRI features. PATIENTS AND METHODS: From 2008 to 2012, 135 patients were selected for AS using Epstein criteria...
November 21, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29239845/oncologic-effect-of-cumulative-smoking-exposure-in-patients-treated-with-salvage-radical-prostatectomy-for-radiation-recurrent-prostate-cancer
#13
Andrea Mari, Mohammad Abufaraj, Beat Foerster, Mehmet Özsoy, Alberto Briganti, Morgan Rouprêt, Pierre I Karakiewicz, Romain Mathieu, David D'Andrea, Daher C Chade, Shahrokh F Shariat
INTRODUCTION: The purpose of the present study was to investigate the association of smoking with biochemical recurrence (BCR) and metastasis in radiation-recurrent prostate cancer (PCa) patients undergoing salvage radical prostatectomy (SRP). PATIENTS AND METHODS: A total of 214 patients treated with SRP for radiation-recurrent PCa in 5 tertiary referral centers were included from January 2007 to December 2015. Kaplan-Meier analyses were used to assess the time to BCR and metastasis...
November 10, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29196209/pathologic-outcomes-of-gleason-6-favorable-intermediate-risk-prostate-cancer-treated-with-radical-prostatectomy-implications-for-active-surveillance
#14
David D Yang, Brandon A Mahal, Vinayak Muralidhar, Marie E Vastola, Ninjin Boldbaatar, Shelby A Labe, Michelle D Nezolosky, Peter F Orio, Martin T King, Neil E Martin, Kent W Mouw, Quoc-Dien Trinh, Paul L Nguyen
BACKGROUND: The safety of active surveillance (AS) for Gleason 6 favorable intermediate-risk (FIR) prostate cancer is unknown. To provide guidance, we examined the incidence and predictors of upgrading or upstaging for Gleason 6 FIR patients treated with radical prostatectomy. PATIENTS AND METHODS: We identified 2807 men in the National Cancer Database diagnosed from 2010 to 2012 with Gleason 6 FIR disease (<50% positive biopsy cores [PBC] with either prostate-specific antigen [PSA] of 10-20 ng/mL or cT2b-T2c disease) treated with radical prostatectomy...
November 9, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29239847/metastatic-primitive-neuroectodermal-tumor-of-the-prostate-a-case-report-and-review-of-the-literature
#15
Ali Kord Valeshabad, Paul Choi, Nour Dababo, Ejaz Shamim, Alaa Alsadi, Karen L Xie
No abstract text is available yet for this article.
November 7, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29239846/molecular-subtypes-of-clear-cell-renal-cell-carcinoma-are-associated-with-outcome-during-pazopanib-therapy-in-the-metastatic-setting
#16
Annelies Verbiest, Gabrielle Couchy, Sylvie Job, Jessica Zucman-Rossi, Laure Caruana, Evelyne Lerut, Raymond Oyen, Aurélien de Reyniès, Brigitte Laguerre, Nathalie Rioux-Leclercq, Agnieszka Wozniak, Steven Joniau, Hendrik Van Poppel, Kathleen Van Den Eynde, Benoit Beuselinck
BACKGROUND: We previously described 4 molecular subtypes of metastatic clear cell renal cell carcinoma (mccRCC), named ccrcc1-4 (Beuselinck et al, 2015). These have both prognostic and predictive value for patients treated with first-line sunitinib, with distinctive objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). The ccrcc2 and ccrcc3 tumors have the best outcomes, followed by ccrcc1 and then ccrcc4. We hypothesized that these molecular subtypes would show similar outcomes with first-line pazopanib treatment...
November 7, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29239844/selected-high-risk-patients-with-upper-tract-urothelial-carcinoma-treated-with-radical-nephroureterectomy-for-adjuvant-chemotherapy-a-multi-institutional-retrospective-study
#17
Masaomi Ikeda, Kazumasa Matsumoto, Takahiro Hirayama, Dai Koguchi, Yasukiyo Murakami, Daisuke Matsuda, Norihiko Okuno, Takuji Utsunomiya, Yoshinori Taoka, Akira Irie, Masatsugu Iwamura
BACKGROUND: No definitive evidence exists regarding use of adjuvant chemotherapy (AC) for high-risk cases after radical nephroureterectomy (RNU), and the benefit of AC remains controversial. The aims of this study were to evaluate the efficacy of AC in patients with upper tract urothelial carcinoma (UTUC) and to determine those who qualified for AC. PATIENTS AND METHODS: From 1990 to 2015, 449 patients with nonmetastatic UTUC underwent RNU at 6 Kitasato University-affiliated hospitals...
November 7, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29196208/eradicate-a-prospective-evaluation-combining-radium-223-dichloride-and-abiraterone-acetate-plus-prednisone-in-patients-with-castration-resistant-prostate-cancer
#18
Neal D Shore, Ronald F Tutrone, Neil F Mariados, Luke T Nordquist, Bryan A Mehlhaff, Karyn J Steere, Stacey S Harrelson
BACKGROUND: Multiple castration-resistant prostate cancer (CRPC) therapies are approved by the United States Food and Drug Administration. Radium-223 dichloride (Ra-223) with abiraterone acetate plus prednisone have different mechanisms of action and distinct off-target side-effect profiles. We prospectively investigated their combined safety, tolerability, and patient-reported outcome measures. PATIENTS AND METHODS: eRADicAte, an investigator-initiated, phase II trial, studied 31 patients with metastatic CRPC, from 5 United States uro-oncology research sites...
November 7, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29174504/intravesical-immunomodulatory-imiquimod-enhances-bacillus-calmette-gu%C3%A3-rin-downregulation-of-nonmuscle-invasive-bladder-cancer
#19
Juliana A Camargo, Gabriela R Passos, Karen L Ferrari, Athanase Billis, Mário J A Saad, Leonardo O Reis
BACKGROUND: The Toll-like receptor (TLR)2/4 agonist bacillus Calmette-Guérin (BCG), although not failure proof, has been the most efficient immunomodulatory treatment of immunogenic nonmuscle-invasive bladder cancer (NMIBC) for > 40 years. We investigated the role of the immunomodulatory molecule TLR7 agonist imiquimod through the BCG key receptors TLR2/4 and the main downstream molecules of the mammalian target of rapamycin pathway in NMIBC treatment. MATERIALS AND METHODS: A total of 40 Fischer-344 rats, 7 weeks old, received 4 doses of 1...
November 7, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29174503/external-validation-of-the-arterial-based-complexity-score-and-first-head-to-head-comparison-with-the-r-e-n-a-l-and-padua-scores-and-c-index
#20
Alessandro Antonelli, Alessandro Veccia, Marco Sandri, Maria Chiara Furlan, Stefano Recenti, Mario Sodano, Carlotta Palumbo, Alberto Cozzoli, Claudio Simeone
INTRODUCTION: We performed an external validation of the arterial-based complexity (ABC) score using a head-to-head comparison with the R.E.N.A.L. (radius, exophytic/endophytic tumor properties, nearness of tumor to deepest portion of collecting system or sinus, anterior/posterior descriptor, location relative to the polar line), PADUA (preoperative aspects and dimension for anatomic classification of renal tumors), and C-index scores for the prediction of surgical outcomes after partial nephrectomy...
November 7, 2017: Clinical Genitourinary Cancer
journal
journal
41208
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"